Mitsubishi UFJ Asset Management Co. Ltd. Boosts Stock Position in Amgen Inc. $AMGN

Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 3.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,237,508 shares of the medical research company’s stock after buying an additional 44,044 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.23% of Amgen worth $349,225,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen in the second quarter valued at $27,000. Evelyn Partners Investment Management LLP purchased a new position in shares of Amgen during the 2nd quarter worth about $32,000. Howard Hughes Medical Institute acquired a new stake in shares of Amgen in the second quarter worth approximately $32,000. Quaker Wealth Management LLC grew its holdings in Amgen by 200.0% in the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 240 shares during the period. Finally, Cloud Capital Management LLC acquired a new position in Amgen during the third quarter worth approximately $34,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Royal Bank Of Canada boosted their price objective on shares of Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research note on Wednesday, February 4th. Cantor Fitzgerald raised their price objective on Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Leerink Partners boosted their target price on Amgen from $305.00 to $355.00 and gave the stock an “outperform” rating in a report on Wednesday, February 4th. Mizuho lifted their price target on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Finally, BMO Capital Markets increased their price objective on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Amgen has an average rating of “Moderate Buy” and an average price target of $351.76.

Amgen Stock Performance

Shares of AMGN stock opened at $384.33 on Thursday. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $387.49. The company has a market cap of $207.18 billion, a P/E ratio of 27.01, a PEG ratio of 3.79 and a beta of 0.46. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The business has a 50 day moving average of $346.58 and a two-hundred day moving average of $318.34.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period last year, the business posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.6%. Amgen’s payout ratio is presently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.